The cost of treatment with
CytoSorb® will now be covered by the public sector in
Turkey
PRINCETON, N.J., Aug. 23,
2022 /PRNewswire/ -- CytoSorbents
Corporation (NASDAQ: CTSO), a leader in the treatment of
life-threatening conditions in the intensive care unit and cardiac
surgery using blood purification via its proprietary polymer
adsorption technology, announced that the Turkish Ministry of
Health has approved national reimbursement for CytoSorb®, which is
now a reimbursed catalog product in the State Supply Office of
Turkey (DMO) portal and can be
purchased directly by hospitals and physicians without
restrictions.
CytoSorb obtains Turkish reimbursement,
enabling new dimension of blood purification for critical care
& cardiac surgery
Dr. Christian Steiner, Executive
Vice President, Sales and Marketing of CytoSorbents, stated, "We
greatly appreciate the Turkish Ministry of Health's recognition of
the important role CytoSorb can play in the management of complex
patients who are critically ill or are undergoing cardiothoracic
surgery. Each year in Turkey, there are an estimated 140,000
patients treated in the ICU for severe sepsis or septic shock
related to infection, with a high risk of death. There are also
more than an estimated 75,000 patients who undergo cardiothoracic
surgery annually, many of whom are medical tourists treated in
private hospitals. In addition, there are numerous other
critically ill patients suffering from other life-threatening
conditions such as acute lung or liver failure, trauma, and others
where CytoSorb can be used to control deadly inflammation and
provide organ support. Now with reimbursement, more patients
will have access to our breakthrough CytoSorb therapy that adds a
new dimension to blood purification."
Dr. Steiner praised the strategic collaboration with new
distribution partner, Bıçakcılar Medical Devices. "Our partnership
with Bıçakcılar was instrumental in obtaining national
reimbursement and inclusion of CytoSorb® in the healthcare catalog
of the DMO. We look forward to working more closely with them to
leverage our new reimbursement and expand the Turkish market for
our products."
Bıçakcılar Medical Devices is the leading manufacturer of
disposable medical products and OR Solutions in Turkey. The company was established in
1959. Over the years, the Bıçakcılar brand has gained wide
acceptance and established a tradition of continued reliability and
customer satisfaction.
Dr. Souheil El Hakim, Chief
Executive Officer of Bıçakcılar, emphasized the important alignment
of both companies towards patient-centric solutions that are vital
to improving clinical outcomes for critically ill patients in
Turkey and beyond. "We believe
that everyone deserves affordable and effective healthcare.
In critical care medicine specifically, we are able to
distribute the most effective therapies with the help of our
extensive production facilities. At the same time, we are
working to have a direct impact on healthcare outcomes. With
CytoSorbents, we have found one of the most innovative partners to
help us achieve this, giving us the opportunity to fill our
approach with even more life."
Turkey provides universal
health care for approximately 95% of the nation's 84 million
citizens, comparable in size to Germany. There are more than
1,500 hospitals, where roughly 62% are public or university
hospitals, and 38% are private. Turkey has a large intensive care unit
network, with one of the highest numbers of ICU beds per 100,000
population among developed nations at roughly 46, compared to 29 in
the U.S. and 39 in Germany, for
example. Turkey is also a
central hub for medical tourism in the region, attracting 1.7
million patients from outside of Turkey each year, particularly for surgical
procedures such as cardiovascular, thoracic, plastic, orthopedic,
and others.
About Bıçakcılar Medical
Bıçakcılar Medical is a 60-year-old company that has created a
lot of "firsts" in Turkey where it
was born. Over the years, expanding globally, Bıçakcılar Medical
has helped to save lives around the world supplying the products
that are crucial in healthcare. From medical disposables to OR
Solutions, it stands out with two unique attributes: Quality
control with zero tolerance for error and after sales service by
its own experts, adding exceptional durability to its medical
equipment. A focus on the "patient" is just one of the reasons many
of its international and domestic customers have partnered with the
company for over 20 years. With over 800 employees and many
business partners, Bıçakcılar serves its customers by manufacturing
and supplying innovative, reliable and environmentally friendly
medical devices. Bıçakcılar is committed to assuring that
everything it does benefits society and the environment while
helping to save lives.
About CytoSorbents Corporation
(NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in critical care and cardiac surgery
through blood purification. Its flagship product, CytoSorb®,
is approved in the European Union and marketed in more than 70
countries worldwide. It is an extracorporeal cytokine adsorber
designed to reduce the "cytokine storm" or "cytokine release
syndrome" that occurs in common critical illnesses and can lead to
massive inflammation, organ failure and patient death. In these
diseases, the risk of death can be extremely high, and there are
few, if any, effective treatments. CytoSorb is also used
during and after cardiothoracic surgery to remove inflammatory
mediators that can lead to postoperative complications, including
multiple organ failure. As of June 30,
2022, more than 179,000 CytoSorb devices have been used
cumulatively worldwide. CytoSorb was originally launched in
the European Union under the CE Mark as the first extracorporeal
cytokine adsorber. Additional CE Mark extensions were granted for
bilirubin and myoglobin removal in clinical conditions such as
liver disease and trauma, respectively, and for ticagrelor and
rivaroxaban removal during cardiothoracic surgery. CytoSorb
has also received FDA emergency approval in the United States for use in adult critically
ill COVID-19 patients with impending or confirmed respiratory
failure. The DrugSorb™-ATR antithrombotic removal system,
based on the same polymer technology as CytoSorb, also received FDA
Breakthrough Device Designation to remove ticagrelor and FDA
Breakthrough Device Designation to remove the direct oral
anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary
bypass circuit during urgent cardiothoracic procedures. The
company has initiated two FDA-approved pivotal studies to support
marketing approval of DrugSorb-ATR in the United States. The
first is the randomized, controlled STAR-T (Safe and Timely
Antithrombotic Removal-Ticagrelor) study of 120 patients at 30
centers to evaluate whether intraoperative use of DrugSorb-ATR can
reduce perioperative bleeding risk in ticagrelor patients
undergoing cardiothoracic surgery. The second study is the
STAR‑ D (Safe and Timely Antithrombotic Removal-Direct Oral
Anticoagulants) randomized controlled trial of 120 patients at 30
centers evaluating the intraoperative use of DrugSorb-ATR to reduce
perioperative bleeding risk in patients undergoing cardiothoracic
surgery who are taking direct oral anticoagulants, including
apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other body fluids through pore
entrapment and surface adsorption. The Company's technologies
have received more than $39.5 million
in non-dilutive grants, contracts and other funding from DARPA, the
U.S. Department of Health and Human Services (HHS), the National
Institutes of Health (NIH), the National Heart, Lung, and Blood
Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special
Operations Command (SOCOM), Air Force Material Command (USAF/AFMC)
and others. The company has numerous marketed and
in-development products based on this unique blood purification
technology protected by numerous issued U.S. and international
patents and registered trademarks, as well as several pending
patent applications, including ECOS-300CY®, CytoSorb-XL™,
HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more
information, please visit the company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on Facebook
and Twitter.
Forward-Looking
Statements
This press release contains forward-looking statements that fall
within the safe harbor of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not
limited to, statements regarding our plans, objectives, future
goals and prospects for our business, expectations regarding the
future impact of COVID-19 or the ongoing conflict between
Russia and Ukraine, representations and assertions, and
are not historical facts and are generally identified by the use of
words such as "may," "should," "could," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar terms, although some forward-looking
statements are worded differently. You should be aware that the
forward-looking statements in this press release reflect
management's current beliefs and expectations, but that our actual
results, events and performance may differ materially from those in
the forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, the
risks disclosed in our Annual Report on Form 10-K filed with the
SEC on March 10, 2022, our Quarterly
Reports on Form 10-Q and the press releases and other
communications to stockholders that we issue from time to time
seeking to inform interested parties of the risks and factors that
may affect our business. We caution you not to place undue reliance
on such forward-looking statements. We are under no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by federal securities laws.
Please click to follow us on Facebook and Twitter
U.S. Company Contact:
Amy
Vogel
305 College Road East
Princeton, NJ 08540
+1 (732) 329-8885
avogel@cytosorbents.com
European Company Contact:
Josephine Kraus
+49 30 765 84 66 23
josephine.kraus@cytosorbents.com
U.S. Public Relations:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
European Public Relations:
Marcus Schult
commponists
+49 69 13823 ext. 960
+49 172 4238938
marcus.schult@die-kommponisten.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/turkish-ministry-of-health-grants-national-reimbursement-to-cytosorb-301610442.html
SOURCE CytoSorbents Corporation